Company intelligence / Profile preview

Torigen Pharmaceuticals

Farmington, Connecticut, United Statestorigen.com ↗

Ownership: Private
Development stage: Commercial

Overview

Torigen has commercialized a personalized autologous cancer vaccine for companion animals. The product is used by approximately 500 veterinary clinics across the United States. Early clinical and real-world data support its use as an adjunct or alternative to traditional therapies like chemotherapy and radiation. A second-generation version of their vaccine is currently undergoing safety testing[2][3].

Therapeutic areas: Oncology
Modalities: Autologous cancer vaccines (personalized immunotherapy)Immunotherapy based on tumor antigens[1][3][5]
Industry: Veterinary

Drug pipeline

1 asset

VetiVax

Commercial

Indications: Cancer

Partnerships

Partnerships with human oncology companies to adapt novel assets for the veterinary market[3]

Beyond the preview

Go deeper on Torigen Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Torigen Pharmaceuticals.